Russian-American lobbyist confirms attending Donald Trump Jr. meeting

Trump Tower Meeting Who Was All There

The outlet said the lobbyist was suspected of having ties to Russian intelligence agencies.

Ahkmetshin told AP that he did not consider the meeting to be "substantive" and had been expecting a "more serious" conversation. Trump Jr. agreed to the meeting because he thought he would be receiving damaging information about Hillary Clinton.

But like a Russian nesting doll, the number of bodies present at Trump Jr.'s meeting somehow keeps multiplying.

Although Trump Jr. has insisted that Vesenikstaya mainly wanted to talk about Russian adoptions, Akhmetshin said she brought a folder with information about an American hedge fund operating in Russia that she believed was funneling money to the Democratic National Committee.

The sticky web of denial and deception surrounding the Trump presidential campaign's contacts with Russian officials and their go-betweens grew larger this week.

Akhmetshin is a dual U.S. The person Futerfas spoke to told the lawyer that he was not working for the Russian government, according to NBC.

"No, that I didn't know until a couple of days ago when I heard about this", Trump said when asked if he knew his eldest son was meeting with Russian attorney Natalia Veselnitskaya.

Earlier this year, Trump Jr. denied in an interview with The New York Times that he had participated in a "setup" meeting with a Russian.

File image of Donald Trump with Donald Jr.

Alan Futerfas, Trump Jr.'s lawyer, told The Hill that the lobbyist mentioned in NBC's report was introduced as a "friend of Veselnitskaya".

"They couldn't wait for the meeting to end", he reportedly said.

Details about the meeting emerged this week as investigators in the House, Senate and Justice Department continue to conduct separate probes concerning last year's presidential election, particularly with respect to whether the Trump campaign colluded in any way with Russian actors. However, accepting campaign opposition research from a foreign government is not a common practice.

Later yesterday, a spokesman for the president's outside legal team contended that participants in the June meeting "misrepresented who they were and who they worked for".

His comment came after a Dow Jones story on Saturday, reported through Fox Business News, that noted Wall Street analysts' forecasts are projecting earnings of near double digits, which would put the second quarter reports at among the best place since the fourth quarter of 2011.

The disclosure form doesn't specify whether Futerfas' payment was meant to be for his representation of Trump's son or someone else.

Related:

Comments

Latest news

This Jaguar did the world's largest barrel roll
Jaguar Land Rover's full range of turbocharged four-cylinder petrol and diesel Ingenium engines will be offered in the E-Pace. He said the E-Pace may be a family's only vehicle and that it has been created to cater to those who value connectivity.

Panama rally for 2-1 CONCACAF Gold Cup win over Nicaragua
And, while he didn't score on Wednesday, he also presented a strong case for more playing time for the remainder of the Gold Cup. A minute after Morris' missed opportunity, Gonzalez scored his second career worldwide goal by stabbing a rebound past Olimpa.

Trump defends son's meeting, says most people would have taken it
Of course, behind the scenes both Macron and Trump will spell out their respective visions on many important global issues. Trump arrived July 13, and will be the guest of honor during the Bastille Day military parade July 14.

Chicago Cubs land LHP Jose Quintana in trade with Chicago White Sox
Also, starter John Lackey , 38, has been coping with plantar fasciitis in his right foot for at least his past couple starts. Jimenez is only 20 and has a.271/.351/.490 slash line in High-A with six doubles, two triples and eight homers in 42 games.

'Astounding' second-chance cancer drug heading for FDA approval
The trial lacked a control group, so investigators can not yet say with certainty how much of an effect the treatment had. The committee decision now gets passed to the FDA which is expected to render a final decision regarding CTL109 by Oct.3.

Other news